The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) plans to help bring a vaccine for the Zika virus to market immediately via Emergent BioSolutions Inc., which also developed the anthrax vaccine.
Emergent BioSolutions said that it obtained a contract with ASPR’s Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture three cGMP lots of a Zika vaccine for use in a phase 1 clinical trial is valued at up to $21.9 million.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) plans to help bring a vaccine for the Zika virus to market immediately via Emergent BioSolutions Inc., which also developed the anthrax vaccine.
Emergent BioSolutions said that it obtained a contract with ASPR’s Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture three cGMP lots of a Zika vaccine for use in a phase 1 clinical trial is valued at up to $21.9 million.